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Background: Qatar has experienced a large SARS-CoV-2 epidemic. Our first objective was to 
assess the proportion of the urban population that has been infected with SARS-CoV-2, by 
measuring the prevalence of detectable antibodies. Our second objective was to identify 
predictors for infection and for having higher antibody titers.  
Methods: Residual blood specimens from individuals receiving routine and other clinical care 
between May 12-September 9, 2020 were tested for anti-SARS-CoV-2 antibodies. Associations 
with seropositivity and higher antibody titers were identified through regression analyses. 
Probability weights were applied in deriving the epidemiological measures. 
Results: We tested 112,941 individuals (~10% of Qatar’s urban population), of whom 51.6% 
were men and 66.0% were 20-49 years of age. Seropositivity was 13.3% (95% CI: 13.1-13.6%) 
and was significantly associated with sex, age, nationality, clinical-care type, and testing date. 
The proportion with higher antibody titers varied by age, nationality, clinical-care type, and 
testing date. There was a strong correlation between higher antibody titers and seroprevalence in 
each nationality, with a Pearson correlation coefficient of 0.85 (95% CI: 0.47-0.96), suggesting 
that higher antibody titers may indicate repeated exposure to the virus. The percentage of 
antibody-positive persons with prior PCR-confirmed diagnosis was 47.1% (95% CI: 46.1-
48.2%), severity rate was 3.9% (95% CI: 3.7-4.2%), criticality rate was 1.3% (95% CI: 1.1-
1.4%), and fatality rate was 0.3% (95% CI: 0.2-0.3%).  
Conclusions: Fewer than two in every 10 individuals in Qatar’s urban population had detectable 
antibodies against SARS-CoV-2 between May 12-September 9, 2020, suggesting that this 
population is still far from the herd immunity threshold and at risk from a subsequent epidemic 
wave.   
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With the breakthrough development of highly efficacious vaccines against the severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2) [1-3], determining the population’s 
cumulative infection exposure and current immunity level is critical to inform national vaccine 
roll-out strategies.  
Qatar, located in the Arabian peninsula, with a multinational population of 2.8 million people, 
nearly all living in the capital city, Doha, had a significant first wave of COVID-19 that peaked 
in late May 2020 [4,5]. As of December 23, 2020, >60,000 infections per million population had 
been laboratory-confirmed [6,7]. Qatar has a unique socio-demographic structure, in which 
single-unit and family households including children, adults and/or older adults, account for only 
40% of the total population, with adults in this “urban population” often being part of the 
professional or service workforce [4,8,9]. The remaining 60% of the population consists of craft 
and manual workers (CMWs) [4,8,9]—mostly single, young men working in development 
projects [9] and typically living in large, shared accommodations [10]. 
Infection transmission in Qatar was first documented among CMWs on March 6, 2020 [11], who 
were subsequently most affected by this epidemic [12]. A recently completed nationwide, 
population-based survey assessing “ever” infection among the CMW population found that six 
out of every ten persons had detectable antibodies against SARS-CoV-2, suggesting that this 
population is at or near herd immunity [13]. In the present study, the first objective was to assess 
the level of infection exposure among the rest of the population of Qatar, that of the “urban 
population” of this country. The second objective was to identify predictors for infection and for 
having higher antibody titers. 
Methods 
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A cross-sectional serological study was conducted from May 12 to September 9, 2020 to assess 
the level of and associations with antibody positivity in the urban population of Qatar. The 
sample included residual blood specimens collected from individuals receiving routine and other 
clinical care at Hamad Medical Corporation (HMC), a main provider of healthcare to the urban 
population of this country and the nationally designated provider for Coronavirus Disease 2019 
(COVID-19) healthcare needs. 
Antibody data generated during the study were subsequently linked to the national centralized 
SARS-CoV-2 polymerase chain reaction (PCR) testing and hospitalization database, which 
includes records for all PCR testing and COVID-19 hospitalizations in Qatar since the start of 
the epidemic [14]. The database further includes the severity classification of hospitalized cases, 
based on individual chart reviews completed by trained medical personnel using the World 
Health Organization (WHO) criteria [15]. The study was approved by the HMC and Weill 
Cornell Medicine-Qatar Institutional Review Boards. The study was conducted following the 
ethics review boards guidelines and regulations. 
Laboratory methods  
Roche Elecsys® Anti-SARS-CoV-2 (Roche, Switzerland), an electrochemiluminescence 
immunoassay, was used for antibody detection in serological samples. Result interpretation 
followed manufacturer instructions: reactive for optical density (a proxy for antibody titer) cutoff 
index ≥1.0 and non-reactive for cutoff index <1.0 [16].  
Current infection was assessed using PCR testing of aliquots of Universal Transport Medium 
(UTM) used for nasopharyngeal and oropharyngeal swab collection (Huachenyang Technology, 
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China). Aliquots were extracted on the QIAsymphony platform (QIAGEN, USA) and tested with 
real-time reverse-transcription PCR (RT-qPCR) using the TaqPath™ COVID-19 Combo Kit 
(Thermo Fisher Scientific, USA) on an ABI 7500 FAST (Thermo Fisher, USA). Samples were 
extracted using a custom protocol [17] on a Hamilton Microlab STAR (Hamilton, USA) and 
tested using the AccuPower SARS-CoV-2 Real-Time RT-PCR Kit (Bioneer, Korea) on an ABI 
7500 FAST, or loaded directly into a Roche cobas® 6800 system and assayed with the cobas® 
SARS-CoV-2 Test (Roche, Switzerland). All laboratory testing was conducted at HMC Central 
Laboratory following standardized protocols. 
Statistical analysis 
Frequency distributions were used to describe sample characteristics and optical density among 
antibody-positive persons. Probability weights were applied to generate estimates representing 
the wider urban population. Weights were developed using population distributions by sex, age 
group, and nationality in the Primary Health Care Corporation (PHCC) database [18]. This 
database essentially covers the urban population of Qatar and includes 1,468,837 registered 
users, distributed across Qatar’s 27 PHCC centers [18].   
Associations with anti-SARS-CoV-2 positivity, as well as with higher antibody titers (defined as 
optical density higher than the median value) were investigated using chi-square tests and 
univariable logistic regression. Covariates with p-values ≤0.2 in univariable regression analysis 
were included in the multivariable model. Covariates with p-values ≤0.05 in the multivariable 
analysis were regarded as strong evidence for an association with the outcome. Odds ratios 
(ORs), adjusted ORs (AORs), 95% confidence intervals (CIs), and p-values were reported.  
The antibody database was linked to the SARS-CoV-2 PCR testing and hospitalization database 
to enable estimation of other epidemiologic metrics. The latter included the proportion of 
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antibody-positive persons who had a diagnosis of SARS-CoV-2 confirmed by PCR prior to the 
antibody test. Numbers of infections that were classified as severe, critical, or fatal, according to 
WHO criteria [15], among all antibody-positive persons, were used to estimate severity, 
criticality, and fatality rates.  
Results 
In all, 112,941 individuals were tested, representing ~10% of the urban population of Qatar [4] 
(Table 1). Of these, 51.6% were men. Two-thirds (66%) of tested persons were 20-49 years of 
age. Qatari (25.8%) and Indian nationals (16.5%) were most heavily represented in the sample, 
reflecting their representation in the urban population [5,8,19]. Specimens were collected in the 
course of routine clinical care during home care visits (34.2%), outpatient visits (28.5%), 
inpatient hospital stays (21.0%), and emergency department visits (16.4%). Overall, the sample 
mirrored the urban population demographics [5,8,9]. 
A total of 18,844 individuals had detectable SARS-CoV-2 antibodies—a weighted antibody 
positivity of 13.3% (95% CI: 13.1-13.6%). Seropositivity was independently associated with sex, 
age, nationality, clinical-care type, and calendar date of the antibody test in the multivariable 
regression analysis (Table 1). Men had two-fold higher odds of being seropositive (AOR of 2.07; 
95% CI: 1.95-2.21) than women. Similarly, the AOR was two-fold higher for adults 20-79 years 
of age than for children <10 years of age. Seropositivity varied by nationality. Compared to other 
nationalities, AOR was 5.05 (95% CI: 4.63-5.50) for Bangladeshis, 4.26 (95% CI: 3.87-4.69) for 
Nepalese, 3.45 (95% CI: 3.07-3.87) for Pakistanis, 1.95 (95% CI: 1.80-2.13) for Indians, 1.85 
(95% CI: 1.60-2.13) for Sri Lankans, 1.59 (95% CI: 1.41-1.78) for Filipinos, 1.36 (95% CI: 1.15-
1.61) for Sudanese, 1.33 (95% CI: 1.19-1.48) for Egyptians, and 0.95 (95% CI: 0.86-1.04) for 
Qataris. Compared to emergency department attendees, AOR was 0.87 (95% CI: 0.81-0.94) for 
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outpatients and 0.72 (95% CI: 0.66-0.78) for patients with home-care visits or follow-up 
consultations, and 1.19 (95% CI: 1.10-1.28) for inpatients. There was evidence of increasing 
seropositivity over time (Table 1 and Table S1 of Supplementary Information (SI)), but at a slow 
rate. The AOR (per day) was 1.002 (95% CI: 1.001-1.003; Table 1). 
Figure 1 illustrates the distribution of antibody titers (optical density values) among the 18,844 
antibody-positive persons. Optical density values ranged from 1.0 to 150.0 with a median of 
27.0. Having higher antibody titers than the median was not associated with sex, but in the 
multivariable regression analysis they were independently associated with age, nationality, 
clinical-care type, and the calendar date of the antibody test (Table 2). Compared to those aged 
20-29 years, the AOR was higher in children <10 years and adults aged 40-79 years. There were 
significant differences by nationality. AOR was 1.68 (95% CI: 1.45-1.94) for Bangladeshis, 1.54 
(95% CI: 1.32-1.80) for Nepalese, 1.30 (95% CI: 1.05-1.61) for Filipinos, 1.22 (95% CI: 1.05-
1.43) for Indians, 1.19 (95% CI: 0.98-1.44) for Pakistanis, 1.12 (95% CI: 0.87-1.44) for Sri 
Lankans, 1.04 (95% CI: 0.77-1.41) for Sudanese, 0.82 (95% CI: 0.67-1.01) for Egyptians, and 
0.78 (95% CI: 0.65-0.94) for Qataris. Compared to emergency department attendees, inpatients 
had an AOR for higher antibody positivity of 0.38 (95% CI: 0.34-0.43), while no difference was 
found for outpatients or for patients with home-care visits or follow-up consultations. Having 
higher antibody titers increased with time (Table 2 and Table S2 of SI), with an AOR (per day) 
of 1.011 (95% CI: 1.010-1.013; Table 2). 
There was a strong correlation between the AOR for higher antibody titers in each nationality 
and the corresponding SARS-CoV-2 seroprevalence of that nationality (Figure 2). The Pearson 
correlation coefficient was 0.85 (95% CI: 0.47-0.96), possibly indicating that higher antibody 
titers correlate with repeated exposures to this coronavirus.  
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Of the 18,844 antibody-positive persons, 9,375 had a PCR-confirmed diagnosis prior to the 
antibody-positive test—47.1% (95% CI: 46.1-48.2%) (Table 3). Meanwhile, 1,085 of the 18,844 
antibody-positive persons had or progressed to a severe infection, and 393 had or progressed to 
critical infection. Thus, the infection severity rate was 3.9% (95% CI: 3.7-4.2%), the infection 
criticality rate was 1.3% (95% CI: 1.1-1.4%), and the combined infection severity or criticality 
rate was 5.2% (95% CI: 4.9-5.5%). With exactly 100 COVID-19 deaths recorded among the 
antibody-positive persons, the infection fatality rate was 0.3% (95% CI: 0.2-0.3%).  
Discussion 
The above results indicate that <20% of the urban population of Qatar, which constitutes ~40% 
of the total population and includes nearly all older adults, manifests evidence of prior infection, 
substantially less than the seroprevalence in the CMW part of the population, which was 
estimated recently in a nationwide survey at 55.3% [13]. 
This finding suggests that the lockdown and imposed social and physical distancing restrictions 
have been more successful in slowing transmission in the urban population compared to the 
CMW population. Building on the totality of evidence on the Qatar epidemic [11-13,20,21], this 
is possibly due to differences in the dwelling structure, in that the urban population lives mostly 
in single-unit or family households that each includes a small number of individuals. Meanwhile, 
the CMW population lives mostly in large shared accommodations that each includes a large 
number of individuals. While the lockdown forced individuals to stay more at home, it is typical 
to have more social contacts every day at home in the large shared accommodations than in the 
single-unit or family households, thereby reducing the options for effective social and physical 
distancing. This outcome highlights the role of the “boarding school” effect in respiratory 
infection transmission, seen often in the intense influenza outbreaks in regular and boarding 
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schools [22,23]. This effect has been also seen in the large SARS-CoV-2 outbreaks in nursing 
homes in Europe and the United States [24-26]. 
With a seroprevalence of <20%, the urban population of Qatar remains far below the herd 
immunity threshold, estimated at 60-70% infection exposure [21,27,28]. Accordingly, there 
exists a potential for subsequent waves of infection in this part of the population, though no 
second wave has materialized since the epidemic peaked in late May, 2020, seven months ago 
[12,20]. On the contrary, only a slow increase in seroprevalence has occurred since the peak of 
the first wave (Table S1 of SI), reflecting the actual low incidence of infection in Qatar over the 
last few months [20]. The absence of a second wave, despite the lack of a lockdown and easing 
of many social distancing restrictions, may be explained by an “immunity shield” effect [29] 
arising from the social mixing between the urban and CMW populations, and by effective 
implementation of “ tR  tuning”, an adjustment of restrictions based on the tR  value, by national 
policymakers, to prevent a second wave [20]. 
There were significant differences in seropositivity by sex, age, and nationality. These are 
probably not due to biological differences, but to differences in the likelihood of exposure to the 
infection. Indeed, a small proportion of the specimens tested in this study belonged to CMWs 
who had a higher risk of exposure to the infection than the urban population [13,21]. While 
HMC provides healthcare primarily to the urban population and other providers cater to the 
CMW population, HMC is the main tertiary care center in Qatar, and was also the nationally 
designated provider for COVID-19 healthcare needs. Thus, it is likely that a small proportion of 
specimens, which cannot be estimated precisely, was drawn from CMWs who were hospitalized 
for COVID-19 or other reasons. This may explain the higher antibody positivity of young 
Bangladeshi, Indian, and Nepalese men (Table 1), who form the bulk of the CMW population 
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[13,21]. This may also explain the higher seroprevalence in the blood specimens drawn during 
inpatient or emergency clinical-care, which are more likely to be COVID-19-related, than those 
drawn during outpatient or home care/follow-up consultation clinical-care (Table 1). The higher 
exposure among men 20-69 years of age probably reflects their more frequent work and other 
activities outside the home, whereas men ≥70 years of age, urged through public-health 
messaging to remain at home, were more likely to do so, out of concern about infection severity.  
The proportion of those antibody-positive who had a PCR-confirmed diagnosis prior to the 
antibody-positive test, was 47.1% (Table 3), much higher than the 9.3% in the CMW population  
[13], and that estimated for the total population of Qatar (11.6%) [20]. This is probably because 
study specimens were drawn from individuals receiving healthcare, including those hospitalized 
for COVID-19, people more likely to have been tested for the infection. This fact, along with the 
difference in age structure between the urban and CMW populations [4,8,9,13], may have 
resulted in higher estimates of infection severity, criticality, and fatality rates in this study (Table 
3), compared to the study of the CMW population [13], or model predictions for the entire 
population of Qatar [30]. 
Strikingly, having a higher antibody titer varied by nationality, clinical-care type, and with time 
(Table 2). Variation by nationality is probably an indirect biomarker of re-exposure to infection, 
resulting in repeated immune-system reactivation. This is suggested by the very strong positive 
correlation between the odds of having a higher antibody titer and seroprevalence across the 
nationalities (Figure 2). Lower antibody titers were found in inpatients, but this may reflect 
COVID-19 hospitalizations for recent infections, so that there was not sufficient time for higher 
antibody titers to develop. There was a trend of increasing higher antibody titers over time, 
which may reflect the growing pool of infected persons who have had more time to develop 
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higher levels of detectable antibodies post-infection, or alternatively to being re-exposed to the 
infection. 
This study has some limitations. The sample included individuals attending HMC for routine or 
other clinical care, but this population may not necessarily be representative of the wider urban 
population of Qatar. Some specimens may have been drawn from CMWs, who are not 
representative of the urban population. However, the large sample size, equivalent to ~10% of 
the urban population of Qatar, as well as the probabilistic weighting used in the analysis may 
have reduced inherent biases in our sample. Laboratory methods were based on high-quality, 
validated commercial platforms, such as the Roche platform used for serological testing [16,31]. 
The Roche platform is one of the most extensively used and investigated commercial platforms, 
with a specificity ≥99.8% [16,32,33] and a sensitivity ≥89% [12,31,33]. However, it is possible 
that the less-than-perfect sensitivity, especially for those with recent infections, may have 
underestimated the actual seroprevalence. Indeed, a recent investigation of the performance of 
three automated, commercial, serological platforms in Qatar, including the Roche platform, 
found that each of them missed ≥20% of individuals with past or current infections [34]. 
In conclusion, fewer than two in every 10 individuals in the urban population of Qatar had 
detectable antibodies against SARS-CoV-2, suggesting that this population is still well below the 
herd immunity threshold and is potentially at risk from a subsequent epidemic wave. This 
emphasizes the need to maintain current social and physical distancing restrictions while SARS-
CoV-2 vaccinations are being scaled up throughout the country. The findings also suggest that 
higher antibody titers appear to be a biomarker of repeated exposures to the infection.  
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Table 1. Characteristics of tested individuals (112,941) and antibody positivity. 
Characteristics Tested Antibody positive  Univariable regression 
analysis 
F test Multivariable regression 
analysis 
N (%) N (%*) p-value OR* (95% CI) p-value p-value† AOR* (95% CI) p-value‡ 
Sex         
   Women  54,707 (48.4) 4,387 (8.0) <0.001 1.00   1.00  
   Men 58,234 (51.6) 14,457 (18.3)  2.59 (2.44-2.73) <0.001 <0.001 2.07 (1.95-2.21) <0.001 
Age (years)         
   <10 3,384 (3.0) 243 (7.1) <0.001 1.00   1.00  
   10-19 5,557 (4.9) 407 (7.3)  1.04 (0.87-1.25) 0.633 <0.001 1.21 (1.00-1.46) 0.049 
   20-29 19,271 (17.1) 2,867 (15.0)  2.33 (2.03-2.69) <0.001  2.04 (1.76-2.36) <0.001 
   30-39 31,622 (28.0) 5,533 (16.8)  2.67 (2.33-3.06) <0.001  2.21 (1.91-2.55) <0.001 
   40-49 23,582 (20.9) 4,876 (18.1)  2.91 (2.53-3.34) <0.001  2.47 (2.14-2.85) <0.001 
   50-59 16,363 (14.5) 3,220 (17.9)  2.87 (2.50-3.31) <0.001  2.46 (2.13-2.85) <0.001 
   60-69 8,639 (7.6) 1,281 (15.0)  2.32 (2.00-2.69) <0.001  2.12 (1.82-2.46) <0.001 
   70-79 3,192 (2.8) 315 (10.5)  1.54 (1.29-1.84) <0.001  1.73 (1.44-2.07) <0.001 
   80+ 1,331 (1.2) 102 (7.5)  1.06 (0.83-1.36) 0.621  1.42 (1.10-1.83) 0.007 
Nationality          
   All other nationalities§ 24,799 (22.0) 2,203 (8.0) <0.001 1.00  <0.001 1.00  
   Bangladeshi 7,773 (6.9) 3,471 (41.9)  8.32 (7.66-9.04) <0.001  5.05 (4.63-5.50) <0.001 
   Nepalese 4,962 (4.4) 2,236 (38.2)  7.10 (6.43-7.85) <0.001  4.26 (3.87-4.69) <0.001 
   Pakistani 5,114 (4.5) 1,419 (23.9)  3.61 (3.23-4.04) <0.001  3.45 (3.07-3.87) <0.001 
   Indian 18,590 (16.5) 4,114 (17.5)  2.44 (2.24-2.65) <0.001  1.95 (1.80-2.13) <0.001 
   Sri Lankan 2,252 (2.0) 556 (17.3)  2.40 (2.06-2.81) <0.001  1.85 (1.60-2.13) <0.001 
   Filipino 7,085 (6.3) 1,100 (12.1)  1.59 (1.42-1.77) <0.001  1.59 (1.41-1.78) <0.001 
   Sudanese 3,954 (3.5) 466 (11.3)  1.47 (1.25-1.73) <0.001  1.36 (1.15-1.61) <0.001 
   Egyptian 9,329 (8.3) 1,150 (10.7)  1.38 (1.23-1.53) <0.001  1.33 (1.19-1.48) <0.001 
   Qatari 29,083 (25.8) 2,129 (7.1)  0.88 (0.80-0.97) 0.008  0.95 (0.86-1.04) 0.266 
Clinical-care encounter type         
   Emergency 18,473 (16.4) 3,333 (14.2) <0.001 1.00  <0.001 1.00  
   Inpatient 23,720 (21.0) 6,308 (19.4)  1.45 (1.35-1.57) <0.001  1.19 (1.10-1.28) <0.001 
   Outpatient 32,146 (28.5) 5,264 (13.1)  0.91 (0.85-0.98) 0.011  0.87 (0.81-0.94) 0.001 
   Home care/follow-up consultations 38,602 (34.2) 3,939 (9.2)  0.61 (0.56-0.66) <0.001  0.72 (0.66-0.78) <0.001 
Antibody test date         
   Calendar date (a linear term) 112,941 (100.0) 18,844 (13.3) <0.001 0.999 (0.998-1.000) 0.123 0.123 1.002 (1.001-1.003) <0.001 
AOR, adjusted odds ratio; CI, confidence interval; OR, odds ratio. 
*Estimates are proportions of antibody-positive persons among those tested, weighted by sex, age, and nationality. 
†Covariates with p-value ≤0.2 in the univariable analysis were included in the multivariable analysis. 
‡Covariates with p-value ≤0.05 in the multivariable analysis were considered strong predictors of anti-SARS-CoV-2 positivity. 
§These include other nationalities residing in Qatar.
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Figure 1. Distribution of antibody titers (optical density values) among the 18,844 antibody-positive individuals identified in this 
study. 
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Table 2. Associations of antibody titers (optical densities) higher than the median value (≥27.0) among the 18,844 antibody-positive 
individuals. 
Characteristics Tested Higher antibody titers 
than the median 
Univariable regression 
analysis 
F test Multivariable regression 
analysis 
N (%) N (%*) p-value OR* (95% CI) p-value p-
value† 
AOR* (95% CI) p-value‡ 
Sex         
   Women 4,387 (23.3) 2,175 (52.1) 0.702 1.00  0.702 -- -- 
   Men 14,457 (76.7) 7,244 (51.6)  0.98 (0.88-1.09) 0.702  -- -- 
Age (years)         
   20-29§ 2,867 (15.2) 1,360 (47.6) <0.001 1.00  <0.001 1.00  
   <10 243 (1.3) 170 (70.0)  2.57 (1.92-3.45) <0.001  2.85 (2.12-3.83) <0.001 
   10-19 407 (2.2) 210 (54.0)  1.30 (1.02-1.65) 0.036  1.19 (0.90-1.56) 0.220 
   30-39 5,533 (29.4) 2,701 (48.1)  1.02 (0.92-1.13) 0.692  0.98 (0.88-1.09) 0.678 
   40-49 4,876 (25.9) 2,442 (50.1)  1.11 (1.00-1.22) 0.051  1.13 (1.02-1.26) 0.025 
   50-59 3,220 (17.1) 1,634 (50.8)  1.14 (1.02-1.27) 0.020  1.20 (1.07-1.35) 0.002 
   60-69 1,281 (6.8) 700 (54.2)  1.31 (1.14-1.50) <0.001  1.46 (1.26-1.70) <0.001 
   70-79 315 (1.7) 158 (49.7)  1.09 (0.86-1.38) 0.480  1.38 (1.07-1.77) 0.012 
   80+ 102 (0.5) 44 (41.7)  0.79 (0.52-1.19) 0.254  1.27 (0.82-1.97) 0.281 
Nationality          
   All other nationalities** 2,203 (11.7) 1,064 (51.7) <0.001 1.00  <0.001 1.00  
   Bangladeshi 3471 (18.4) 1,946 (56.2)  1.20 (1.04-1.38) 0.012  1.68 (1.45-1.94) <0.001 
   Nepalese 2,236 (11.9) 1,099 (49.3)  0.91 (0.78-1.06) 0.210  1.54 (1.32-1.80) <0.001 
   Filipino 1,100 (5.8) 507 (46.2)  0.80 (0.65-0.99) 0.038  1.30 (1.05-1.61) 0.017 
   Indian 4,114 (21.8) 2,027 (51.0)  0.97 (0.84-1.13) 0.699  1.22 (1.05-1.43) 0.011 
   Pakistani 1,419 (7.5) 731 (55.5)  1.16 (0.96-1.41) 0.124  1.19 (0.98-1.44) 0.076 
   Sri Lankan 556 (3.0) 242 (45.2)  0.77 (0.59-0.99) 0.044  1.12 (0.87-1.44) 0.392 
   Sudanese 466 (2.5) 264 (53.2)  1.06 (0.78-1.44) 0.712  1.04 (0.77-1.41) 0.789 
   Egyptian 1,150 (6.1) 535 (49.0)  0.90 (0.73-1.10) 0.283  0.82 (0.67-1.01) 0.062 
   Qatari 2,129 (11.3) 1,004 (51.8)  1.00 (0.84-1.21) 0.959  0.78 (0.65-0.94) 0.010 
Clinical-care encounter type         
   Emergency 3,333 (17.7) 1,866 (58.5) <0.001 1.00  <0.001 1.00  
   Outpatient 5,264 (27.9) 3,189 (60.7)  1.10 (0.97-1.25) 0.136  1.06 (0.94-1.21) 0.334 
   Home care/follow-up consultations 3,939 (20.9) 2,195 (58.3)  0.99 (0.86-1.14) 0.915  1.00 (0.87-1.15) 0.987 
   Inpatient 6,308 (33.5) 2,169 (35.2)  0.39 (0.34-0.44) <0.001  0.38 (0.34-0.43) <0.001 
Antibody test date         
   Calendar date (a linear term) 18,844 (100.0) 9,419 (51.8) <0.001 1.014 (1.012-1.016) <0.001 <0.001 1.011 (1.010-1.013) <0.001 
AOR, adjusted odds ratio; CI, confidence interval; OR, odds ratio. 
*Estimates are proportions of persons with antibody titers higher than the median among those antibody-positive, weighted by sex, age, and nationality. 
†Covariates with p-value ≤0.2 in the univariable analysis were included in the multivariable analysis. 
‡Covariates with p-value ≤0.05 in the multivariable analysis were considered strong predictors of anti-SARS-CoV-2 positivity. 
§The 20-29 age group was chosen as the reference group (instead of the <10 age group) because of the larger sample size and for epidemiological relevance.  
**These include other nationalities residing in Qatar. 
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Figure 2. Adjusted odds ratios for higher antibody titers (optical densities higher than the 
median value of 27.0) for each nationality (Table 3) versus the corresponding SARS-CoV-2 
seroprevalence for that nationality (Table 1). 
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Table 3. Key SARS-CoV-2 epidemiological measures assessed in the study. 





Estimate in % 
(95% CI)  
Sample antibody positivity (seropositivity)  112,941 18,844 16.7 (16.5-16.9) 
Weighted antibody positivity (seropositivity)  112,941 18,844 13.3 (13.1-13.6)* 
Proportion with prior PCR-confirmed 
diagnosis† 
18,844 9,375 47.1 (46.1-48.2)* 
Infection severity rate‡ 18,844 1,085 3.9 (3.7-4.2)* 
Infection criticality rate§ 18,844 393 1.3 (1.1-1.4)* 
Infection severity or criticality rate** 18,844 1,478 5.2 (4.9-5.5)* 
Infection fatality rate†† 18,844 100 0.3 (0.2-0.3)* 
PCR, polymerase chain reaction; CI, confidence interval. 
*Estimates weighted by sex, age, and nationality. 
†Proportion of antibody-positive persons who had a prior SARS-CoV-2 PCR-confirmed diagnosis. 
‡Number of infections that were severe per World Health Organization criteria [15] over the total number of antibody-positive persons. 
§Number of infections that were critical per World Health Organization criteria [15] over the total number of antibody-positive persons. 
**Number of infections that were severe or critical per World Health Organization criteria [15] over the total number of antibody-positive persons. 
††Number of COVID-19 deaths per World Health Organization criteria [15] over the total number of antibody-positive persons. 
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Table S1. Results of regression analyses for the association with antibody positivity where antibody test date has been included as a 
categorical term. 
Characteristics Tested Antibody positive  Univariable regression 
analysis 
F test Multivariable regression 
analysis 
N (%) N (%*) p-value OR* (95% CI) p-value p-value† AOR* (95% CI) p-value‡ 
Sex         
   Women  54,707 (48.4) 4,387 (8.0) <0.001 1.00   1.00  
   Men 58,234 (51.6) 14,457 (18.3)  2.59 (2.44-2.73) <0.001 <0.001 2.08 (1.95-2.21) <0.001 
Age (years)         
   <10 3,384 (3.0) 243 (7.1) <0.001 1.00   1.00  
   10-19 5,557 (4.9) 407 (7.3)  1.04 (0.87-1.25) 0.633 <0.001 1.20 (1.00-1.45) 0.056 
   20-29 19,271 (17.1) 2,867 (15.0)  2.33 (2.03-2.69) <0.001  2.03 (1.75-2.35) <0.001 
   30-39 31,622 (28.0) 5,533 (16.8)  2.67 (2.33-3.06) <0.001  2.20 (1.90-2.54) <0.001 
   40-49 23,582 (20.9) 4,876 (18.1)  2.91 (2.53-3.34) <0.001  2.45 (2.13-2.83) <0.001 
   50-59 16,363 (14.5) 3,220 (17.9)  2.87 (2.50-3.31) <0.001  2.45 (2.12-2.83) <0.001 
   60-69 8,639 (7.6) 1,281 (15.0)  2.32 (2.00-2.69) <0.001  2.10 (1.81-2.44) <0.001 
   70-79 3,192 (2.8) 315 (10.5)  1.54 (1.29-1.84) <0.001  1.71 (1.43-2.06) <0.001 
   80+ 1,331 (1.2) 102 (7.5)  1.06 (0.83-1.36) 0.621  1.40 (1.09-1.81) 0.009 
Nationality          
   All other nationalities§ 24,799 (22.0) 2,203 (8.0) <0.001 1.00  <0.001 1.00  
   Bangladeshi 7,773 (6.9) 3,471 (41.9)  8.32 (7.66-9.04) <0.001  5.02 (4.60-5.47) <0.001 
   Nepalese 4,962 (4.4) 2,236 (38.2)  7.10 (6.43-7.85) <0.001  4.23 (3.84-4.66) <0.001 
   Pakistani 5,114 (4.5) 1,419 (23.9)  3.61 (3.23-4.04) <0.001  3.43 (3.06-3.85) <0.001 
   Indian 18,590 (16.5) 4,114 (17.5)  2.44 (2.24-2.65) <0.001  1.95 (1.79-2.12) <0.001 
   Sri Lankan 2,252 (2.0) 556 (17.3)  2.40 (2.06-2.81) <0.001  1.84 (1.59-2.13) <0.001 
   Filipino 7,085 (6.3) 1,100 (12.1)  1.59 (1.42-1.77) <0.001  1.58 (1.41-1.78) <0.001 
   Sudanese 3,954 (3.5) 466 (11.3)  1.47 (1.25-1.73) <0.001  1.36 (1.15-1.61) <0.001 
   Egyptian 9,329 (8.3) 1,150 (10.7)  1.38 (1.23-1.53) <0.001  1.33 (1.19-1.48) <0.001 
   Qatari 29,083 (25.8) 2,129 (7.1)  0.88 (0.80-0.97) 0.008  0.95 (0.86-1.04) 0.264 
Clinical-care encounter type         
   Emergency 18,473 (16.4) 3,333 (14.2) <0.001 1.00  <0.001 1.00  
   Inpatient 23,720 (21.0) 6,308 (19.4)  1.45 (1.35-1.57) <0.001  1.17 (1.08-1.27) <0.001 
   Outpatient 32,146 (28.5) 5,264 (13.1)  0.91 (0.85-0.98) 0.011  0.87 (0.80-0.94) <0.001 
   Home care/follow-up consultations 38,602 (34.2) 3,939 (9.2)  0.61 (0.56-0.66) <0.001  0.70 (0.65-0.76) <0.001 
Antibody test date         
   16 Jun-30 Jun** 11,675 (10.3) 1,919 (11.9) <0.001 1.00  <0.001 1.00  
   12 May-31 May 716 (0.6) 243 (26.2)  2.62 (2.10-3.27) <0.001  1.66 (1.34-2.07) <0.001 
   01 Jun-15 Jun 2,753 (2.4) 704 (18.1)  1.63 (1.43-1.87) <0.001  1.50 (1.31-1.73) <0.001 
   01 Jul-15 Jul 16,294 (14.4) 2,555 (13.2)  1.12 (1.02-1.23) 0.021  1.21 (1.10-1.34) <0.001 
   16 Jul-31 Jul 19,808 (17.5) 3,249 (13.0)  1.11 (1.01-1.21) 0.034  1.21 (1.10-1.34) <0.001 
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   01 Aug-15 Aug 17,319 (15.3) 3,136 (14.3)  1.23 (1.12-1.35) <0.001  1.24 (1.13-1.37) <0.001 
   16-Aug-31 Aug 29,868 (26.4) 4,759 (13.1)  1.11 (1.02-1.21) 0.018  1.35 (1.23-1.48) <0.001 
   01 Sep-09 Sep 14,508 (12.8) 2,279 (13.2)  1.12 (1.01-1.24) 0.030  1.41 (1.26-1.57) <0.001 
AOR, adjusted odds ratio; CI, confidence interval; OR, odds ratio. 
*Estimates are proportions of antibody-positive persons out of those tested weighted by sex, age, and nationality. 
†Covariates with p-value ≤0.2 in the univariable analysis were included in the multivariable analysis. 
‡Covariates with p-value ≤0.05 in the multivariable analysis were considered strong predictors of anti-SARS-CoV-2 positivity. 
§These include other nationalities residing in Qatar. 
**This category was chosen as a reference given the larger sample size and because of the progressive easing of the social and physical distancing restrictions since June 15, 2020 [21].  
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Table S2. Associations for having a higher antibody titer (optical density) than the median value (≥27.0) among 18,844 antibody-
positive individuals, where antibody test date has been included as a categorical term. 




F test Multivariable regression 
analysis 
N (%) N (%*) p-value OR* (95% CI) p-value p-value† AOR* (95% CI) p-value‡ 
Sex         
   Women 4,387 (23.3) 2,175 (52.1) 0.702 1.00  0.702 -- -- 
   Men 14,457 (76.7) 7,244 (51.6)  0.98 (0.88-1.09) 0.702  -- -- 
Age (years)         
   20-29§ 2,867 (15.2) 1,360 (47.6) <0.001 1.00  <0.001 1.00  
   <10 243 (1.3) 170 (70.0)  2.57 (1.92-3.45) <0.001  2.94 (2.19-3.96) <0.001 
   10-19 407 (2.2) 210 (54.0)  1.30 (1.02-1.65) 0.036  1.21 (0.92-1.59) 0.179 
   30-39 5,533 (29.4) 2,701 (48.1)  1.02 (0.92-1.13) 0.692  0.99 (0.89-1.10) 0.816 
   40-49 4,876 (25.9) 2,442 (50.1)  1.11 (1.00-1.22) 0.051  1.16 (1.04-1.30) 0.007 
   50-59 3,220 (17.1) 1,634 (50.8)  1.14 (1.02-1.27) 0.020  1.24 (1.10-1.40) <0.001 
   60-69 1,281 (6.8) 700 (54.2)  1.31 (1.14-1.50) <0.001  1.51 (1.30-1.76) <0.001 
   70-79 315 (1.7) 158 (49.7)  1.09 (0.86-1.38) 0.480  1.43 (1.11-1.84) 0.005 
   80+ 102 (0.5) 44 (41.7)  0.79 (0.52-1.19) 0.254  1.30 (0.83-2.02) 0.247 
Nationality          
   All other nationalities** 2,203 (11.7) 1,064 (51.7) <0.001 1.00  <0.001 1.00  
   Bangladeshi 3471 (18.4) 1,946 (56.2)  1.20 (1.04-1.38) 0.012  1.69 (1.46-1.95) <0.001 
   Nepalese 2,236 (11.9) 1,099 (49.3)  0.91 (0.78-1.06) 0.210  1.54 (1.32-1.81) <0.001 
   Filipino 1,100 (5.8) 507 (46.2)  0.80 (0.65-0.99) 0.038  1.31 (1.05-1.62) 0.016 
   Indian 4,114 (21.8) 2,027 (51.0)  0.97 (0.84-1.13) 0.699  1.23 (1.05-1.43) 0.010 
   Pakistani 1,419 (7.5) 731 (55.5)  1.16 (0.96-1.41) 0.124  1.19 (0.98-1.44) 0.077 
   Sri Lankan 556 (3.0) 242 (45.2)  0.77 (0.59-0.99) 0.044  1.11 (0.87-1.43) 0.395 
   Sudanese 466 (2.5) 264 (53.2)  1.06 (0.78-1.44) 0.712  1.04 (0.77-1.40) 0.802 
   Egyptian 1,150 (6.1) 535 (49.0)  0.90 (0.73-1.10) 0.283  0.83 (0.68-1.01) 0.068 
   Qatari 2,129 (11.3) 1,004 (51.8)  1.00 (0.84-1.21) 0.959  0.80 (0.66-0.96) 0.018 
Clinical-care encounter type         
   Emergency 3,333 (17.7) 1,866 (58.5) <0.001 1.00  <0.001 1.00  
   Outpatient 5,264 (27.9) 3,189 (60.7)  1.10 (0.97-1.25) 0.136  1.11 (0.98-1.26) 0.113 
   Home care/follow-up consultations 3,939 (20.9) 2,195 (58.3)  0.99 (0.86-1.14) 0.915  1.03 (0.90-1.19) 0.628 
   Inpatient 6,308 (33.5) 2,169 (35.2)  0.39 (0.34-0.44) <0.001  0.39 (0.34-0.45) <0.001 
Antibody test date         
   12 May-30 Jun 2,866 (15.2) 846 (31.1) <0.001 1.00  <0.001 1.00  
   01 Jul-15 Jul 2,555 (13.6) 1,190 (46.2)  1.91 (1.62-2.24) <0.001  1.83 (1.53-2.18) <0.001 
   16 Jul-31 Jul 3,249 (17.2) 1,649 (52.4)  2.44 (2.09-2.85) <0.001  2.22 (1.88-2.63) <0.001 
   01 Aug-15 Aug 3,136 (16.6) 1,745 (56.0)  2.82 (2.41-3.29) <0.001  2.51 (2.13-2.96) <0.001 
   16-Aug-31 Aug 4,759 (25.3) 2,719 (58.6)  3.14 (2.72-3.62) <0.001  2.68 (2.29-3.13) <0.001 
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   01 Sep-09 Sep 2,279 (12.1) 1,270 ((58.3)  3.10 (2.60-3.68) <0.001  2.52 (2.10-3.03) <0.001 
AOR, adjusted odds ratio; CI, confidence interval; OR, odds ratio. 
*Estimates are proportions of persons with antibody titers higher than the median among those antibody-positive, weighted by sex, age, and nationality. 
†Covariates with p-value ≤0.2 in the univariable analysis were included in the multivariable analysis. 
‡Covariates with p-value ≤0.05 in the multivariable analysis were considered strong predictors of anti-SARS-CoV-2 positivity. 
§The 20-29 age group was chosen as the reference group (instead of the <10 age group) because of the larger sample size and for epidemiological relevance.  
**These include other nationalities residing in Qatar. 
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